After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

uniQure's gene therapy for Huntington's has hit the mark in a clinical trial, raising hopes of the first treatment for the devastating neurodegenerative disease. Shares in the biotech rose sharply ...

More details have been published of the recently agreed trade agreement between the US and EU, with confirmation the tariff on pharmaceuticals will not exceed 15%. The joint statement does away with ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope to patients of an effective treatment for the relentless itching caused by ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...

Spanish biotech SpliceBio has raised $135 million in financing that will help it move a gene-editing therapy for an inherited retinal disease (IRD) through clinical testing. SpliceBio's lead in-house ...

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category. The Department of Health, NHS England and ...